Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

A multicenter phase II study of gemcitabine and oxaliplatin for malignant pleural mesothelioma.

Schutte W, Blankenburg T, Lauerwald K, Schreiber J, Bork I, Wollscgkaeger B, Treutler D, Schneider CP, Bonner R.

Clin Lung Cancer. 2003 Mar;4(5):294-7.

PMID:
14609447
2.

Cisplatin and gemcitabine in malignant pleural mesothelioma: a phase II study.

Castagneto B, Zai S, Dongiovanni D, Muzio A, Bretti S, Numico G, Botta M, Sinaccio G.

Am J Clin Oncol. 2005 Jun;28(3):223-6. Erratum in: Am J Clin Oncol. 2005 Oct;28(5):444. Sinaccio, G [added].

PMID:
15923792
3.

Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study.

Fizazi K, Doubre H, Le Chevalier T, Riviere A, Viala J, Daniel C, Robert L, Barthélemy P, Fandi A, Ruffié P.

J Clin Oncol. 2003 Jan 15;21(2):349-54.

PMID:
12525529
4.

Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study.

Byrne MJ, Davidson JA, Musk AW, Dewar J, van Hazel G, Buck M, de Klerk NH, Robinson BW.

J Clin Oncol. 1999 Jan;17(1):25-30.

PMID:
10458214
5.

A phase II trial of low-dose gemcitabine in a prolonged infusion and cisplatin for malignant pleural mesothelioma.

Kovac V, Zwitter M, Rajer M, Marin A, Debeljak A, Smrdel U, Vrankar M.

Anticancer Drugs. 2012 Feb;23(2):230-8. doi: 10.1097/CAD.0b013e32834d7a1c.

PMID:
22027538
6.

Phase II trial of gemcitabine/irinotecan in refractory or relapsed small-cell lung cancer.

Schuette W, Nagel S, Juergens S, Bork I, Wollschlaeger B, Schaedlich S, Blankenburg T.

Clin Lung Cancer. 2005 Sep;7(2):133-7.

PMID:
16179101
7.

Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study.

Favaretto AG, Aversa SM, Paccagnella A, Manzini Vde P, Palmisano V, Oniga F, Stefani M, Rea F, Bortolotti L, Loreggian L, Monfardini S.

Cancer. 2003 Jun 1;97(11):2791-7.

8.

Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma.

Shin DM, Fossella FV, Umsawasdi T, Murphy WK, Chasen MH, Walsh G, Komaki R, McMurtrey MJ, Hong WK.

Cancer. 1995 Dec 1;76(11):2230-6.

PMID:
8635025
9.

Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810).

Kalmadi SR, Rankin C, Kraut MJ, Jacobs AD, Petrylak DP, Adelstein DJ, Keohan ML, Taub RN, Borden EC.

Lung Cancer. 2008 May;60(2):259-63. Epub 2007 Nov 19.

10.

Gemcitabine combined with oxaliplatin in pretreated patients with malignant pleural mesothelioma: an observational study.

Xanthopoulos A, Bauer TT, Blum TG, Kollmeier J, Schönfeld N, Serke M.

J Occup Med Toxicol. 2008 Dec 18;3:34. doi: 10.1186/1745-6673-3-34.

11.

A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer.

Kim ST, Park JO, Lee J, Lee KT, Lee JK, Choi SH, Heo JS, Park YS, Kang WK, Park K.

Cancer. 2006 Mar 15;106(6):1339-46.

12.
13.

A phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma: a North Central Cancer Treatment Study, N0021.

Okuno SH, Delaune R, Sloan JA, Foster NR, Maurer MJ, Aubry MC, Rowland KM Jr, Soori GS, Nikcevich DA, Kardinal CG, Northfelt DW, Adjei AA; North Central Cancer Treatment Group.

Cancer. 2008 Apr 15;112(8):1772-9. doi: 10.1002/cncr.23313.

14.

A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma.

Nowak AK, Byrne MJ, Williamson R, Ryan G, Segal A, Fielding D, Mitchell P, Musk AW, Robinson BW.

Br J Cancer. 2002 Aug 27;87(5):491-6.

15.

Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma.

Philip PA, Zalupski MM, Vaitkevicius VK, Arlauskas P, Chaplen R, Heilbrun LK, Adsay V, Weaver D, Shields AF.

Cancer. 2001 Aug 1;92(3):569-77.

PMID:
11505401
16.

Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: a Taiwan cooperative oncology group phase II study.

Ch'ang HJ, Lin YL, Wang HP, Chiu YF, Chang MC, Hsu CH, Tien YW, Chen JS, Hsieh RK, Lin PW, Shan YS, Cheng AL, Chang JY, Whang-Peng J, Hwang TL, Chen LT.

Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):e749-57. doi: 10.1016/j.ijrobp.2010.10.034. Epub 2011 Mar 21.

PMID:
21420250
17.

Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer.

Carles J, Esteban E, Climent M, Font A, Gonzalez-Larriba JL, Berrocal A, Garcia-Ribas I, Marfa X, Fabregat X, Albanell J, Bellmunt J; Spanish Oncology Genito Urinary Group Study Group.

Ann Oncol. 2007 Aug;18(8):1359-62.

PMID:
17693649
18.

A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.

van Meerbeeck JP, Baas P, Debruyne C, Groen HJ, Manegold C, Ardizzoni A, Gridelli C, van Marck EA, Lentz M, Giaccone G.

Cancer. 1999 Jun 15;85(12):2577-82.

PMID:
10375105
19.

Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma.

Ramalingam SS, Belani CP, Ruel C, Frankel P, Gitlitz B, Koczywas M, Espinoza-Delgado I, Gandara D.

J Thorac Oncol. 2009 Jan;4(1):97-101. doi: 10.1097/JTO.0b013e318191520c.

20.

Combination chemotherapy of gemcitabine and vinorelbine for patients in stage IIIB-IV non-small cell lung cancer: a phase II study of the West Japan Thoracic Oncology Group (WJTOG) 9908.

Katakami N, Sugiura T, Nogami T, Yamamoto H, Negoro S, Nakano T, Okamoto N, Takada Y, Kodama K, Ariyoshi Y.

Lung Cancer. 2004 Jan;43(1):93-100.

PMID:
14698543

Supplemental Content

Support Center